Alpine Associates Management Inc. Boosts Stock Position in Catalent, Inc. (NYSE:CTLT)

Alpine Associates Management Inc. raised its position in shares of Catalent, Inc. (NYSE:CTLT) by 3.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,061,251 shares of the company’s stock after acquiring an additional 75,700 shares during the quarter. Catalent makes up approximately 5.5% of Alpine Associates Management Inc.’s holdings, making the stock its 5th largest position. Alpine Associates Management Inc. owned 1.14% of Catalent worth $115,904,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Lindbrook Capital LLC boosted its position in Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalent during the second quarter valued at approximately $42,000. Mather Group LLC. purchased a new position in shares of Catalent during the first quarter valued at approximately $52,000. Longfellow Investment Management Co. LLC lifted its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of Catalent during the fourth quarter valued at approximately $56,000.

Insiders Place Their Bets

In other Catalent news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Catalent news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,409 shares of company stock valued at $782,923. Company insiders own 0.31% of the company’s stock.

Catalent Trading Down 0.1 %

NYSE:CTLT opened at $59.62 on Monday. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 12 month low of $31.80 and a 12 month high of $61.20. The company has a market cap of $10.82 billion, a PE ratio of -9.77, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. The company has a 50 day simple moving average of $59.21 and a two-hundred day simple moving average of $57.11.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Barclays lifted their target price on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com started coverage on shares of Catalent in a report on Tuesday, September 10th. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Catalent presently has a consensus rating of “Hold” and an average target price of $58.08.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.